Vifor blasts FDA's 'reckless' renaming of 4 drugs under the same molecule moniker
Outside of the FDA’s decision to add four-letter, meaningless suffixes on the end of nonproprietary names for biologics, the naming of pharmaceuticals has not been a controversial task in recent years.
But in a new citizen petition filed earlier this month, Switzerland’s Vifor Pharma is raising concerns with the FDA’s decision to change its Orange Book so the active ingredients of four drugs, including three complex IV iron products and Vifor’s chronic kidney disease drug Velphoro, were lumped under the same name of “ferric oxyhydroxide.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.